The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Progesterone and dehydroepiandrosterone, but not estrogen and testosterone, may influence psoriasis pathogenesis, severity ...

board-certified dermatologist and dermapathologist, founding director of Eternal Dermatology in Maryland. But dermatologists say the best way to make your symptoms better is to figure out what could ...

NEW YORK — No fewer than four investigative therapies, ranging from an oral interleukin-23 receptor antagonist to oral tyrosine kinase inhibitors and a long-acting biologic, have the potential to ...

For symptoms of scalp psoriasis, home treatments like olive oil, oatmeal, and apple cider vinegar may provide relief and make ...

Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and ...

Adults with worse cardiovascular-kidney-metabolic health are at an increased risk of developing psoriasis, especially in those with high genetic risk.

A Danish registry study finds no substantial differences in the 5-year risk for first cancers between three biologics in patients with psoriasis.

Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...